P316: PRIORITIZING PRECISION MEDICINES IN PEDIATRIC BLOOD CANCER: EXPERIENCE OF THE DUTCH INDIVIDUALIZED THERAPY (ITHER) STUDY’S MOLECULAR TUMOR BOARD

• Judith M. Boer,
• Uri Ilan,
• Babette D.J. Hoen,
• Aurelie Boeree,
• Karin P.S. Langenberg,
• Jan Koster,
• Jean-Pierre Bourquin,
• Jan J. Molenaar,
• Bianca Goemans,
• Monique L. den Boer,
• Michel Zwaan

Affiliations

Judith M. Boer

1 Princess Máxima Center for pediatric oncology, Research, Utrecht, The Netherlands

Uri Ilan

1 Princess Máxima Center for pediatric oncology, Research, Utrecht, The Netherlands

Babette D.J. Hoen

1 Princess Máxima Center for pediatric oncology, Research, Utrecht, The Netherlands

Aurelie Boeree

1 Princess Máxima Center for pediatric oncology, Research, Utrecht, The Netherlands

Karin P.S. Langenberg

1 Princess Máxima Center for pediatric oncology, Research, Utrecht, The Netherlands

Jan Koster

3 Amsterdam UMC, Department of Oncogenomics, Amsterdam, The Netherlands

Jean-Pierre Bourquin

4 University Children’s Hospital Zurich, Division of Oncology and Children’s Research Center, Switzerland

Jan J. Molenaar

1 Princess Máxima Center for pediatric oncology, Research, Utrecht, The Netherlands

Bianca Goemans

2 Princess Máxima Center for pediatric oncology, Trial and Data Center, Utrecht, The Netherlands

Monique L. den Boer

1 Princess Máxima Center for pediatric oncology, Research, Utrecht, The Netherlands

Michel Zwaan

2 Princess Máxima Center for pediatric oncology, Trial and Data Center, Utrecht, The Netherlands